LOXO-101 sulfate

TypeName: Business Offer
Category:
Offer Date:2019/06/10
Country: United States
Summary: The sulfate salt form of LOXO-101, also called Larotrectinib, which is an ATP-competitive inhibitor of tropomyosin receptor kinases. It was approved by FDA for the treatment of metastatic solid tumors. https://www.bocsci.com/loxo-101-sulfate-cas-1223405-08-0-item-474404.html
Description:
OfferId: 4497
Name:Alex Brown
Telphone:
Categories